Combination chemotherapy is the current strategy of choice for treatment of small cell lung cancer (SCLC). Platinum containing combination regimens are superior to non-platinum regimens in limited stage-SCLC and possibly also in extensive stage-SCLC as first and second-line treatments. The addition of ifosfamide to platinum containing regimens may improve the outcome but at the price of increased toxicity. Suboptimal doses of chemotherapy result in inferior survival. Early intensified, accelerated and high-dose chemotherapy gave conflicting results and is not considered a standard option outside of clinical trials. A number of newer agents have provided promising results when used in combination regimens, for example, gemcitabine, irinotecan and topotecan. However, more studies are required to appropriately evaluate them. There is a definitive role for radiotherapy in LD-SCLC. However, timing and schedule are subject to further research. Novel approaches are currently being investigated in the hope of improving outcome.
Introduction
Lung cancer is the leading cause of cancer death in the developed world. In the UK and many European countries small cell lung cancer (SCLC) accounts for approximately 10-20% of histological types. 1, 2 Until the 1970s, radiotherapy was the standard treatment for SCLC, but this had little effect on survival. The awareness that most patients present with advanced stage disease 3 has led to the use of chemotherapy as the main treatment. In the early 1970s, systemic treatment consisted initially of single agent therapy but in the mid-1970s, a number of studies investigated the efficacy of combination regimens. In the late 1970s, cisplatin emerged as an active agent in SCLC alone and in combination with other chemotherapeutic agents. 4 In the 1980s, attention moved to the use of alternating non-cross resistant regimens and studies testing the role of maintenance chemotherapy. 5 The next decade saw much research into the role of dose intensification for SCLC [6] [7] [8] [9] (Table 1) . Together with chemotherapy, radiotherapy plays an important role in the radical management of SCLC. The results available so far have not yet answered the questions concerning optimum timing, schedule and dose of radiotherapy. Despite the known chemosensitivity of SCLC (response rates of 70-80% with up to 50% complete responses with combination chemotherapy in patients with limited disease), 10 the majority of patients die from recurrent cancer.
The fact that SCLC demonstrates an exquisite sensitivity to chemotherapy and radiotherapy means that studies should be carried out into how best to deliver these types of therapy in order to improve the outcome of patients with this disease. This report presents a review on the use of chemotherapy in the management of SCLC.
Prognostic factors
After a diagnosis of SCLC has been established, careful staging and identification of prognostic factors are necessary to plan treatment. With the therapeutic options currently available, it is important to define the objective of treatment. In frail patients and in those with an adverse prognosis, palliation may be the most realistic option whereas in other patients, aggressive chemotherapy regimens with radiotherapy are justified to aim for long-term survival. A number of multivariate analyses of adverse prognostic factors have been performed in SCLC. In several studies, the parameters identified as having independent prognostic significance included poor performance status, extensive disease, elevated lactate dehydrogenase, high alkaline phophatase, low sodium, low serum albumin, high aspartate aminotransferase and low bicarbonate. 11, 12 The widely used Manchester prognostic score is shown in Table 2 .
The role of combination chemotherapy
Theoretically, combination chemotherapy provides maximum cell kill and provides a broader range of coverage to resistant cell lines in a heterogeneous tumor population preventing or slowing the development of resistant clones. 13 Results of studies comparing single and combination chemotherapy are shown in Table 3 . These confirm superior outcome with a combination chemotherapy approach.
Lowenbraun et al. 14 compared cyclophosphamide with the combina-tion of cyclophosphamide, doxorubicin and dacarbazine (DTIC).
Responding patients and those who did not progress were then randomized to receive their initial regimen alone or their initial regimen with added cycle-active therapy (vincristine, hydroxyurea and methotrexate). Response rates were 12% and 57%, respectively, (P=0.005). Survival for combination-treated patients was significantly better than for those treated with cyclophosphamide alone (P=0.012). Combination treated patients had more treatment related leukopoenia and gastrointestinal toxicity. No quality of life data were available. Two important studies compared single agent with combination chemotherapy in patients with poor prognosis SCLC. 15 18 In the second-line setting, combination chemotherapy was initially found to be more effective than single agent treatment. The response rates obtained by combination of PE or reinduction therapy were 45% and 64%, respectively. With P and E not given in combination, the response rates were less than 20%. 19 
Platinum containing regimens
In the late 1970s, cisplatin emerged as an active agent in SCLC alone and in combination with other chemotherapeutic agents. [20] [21] [22] Cisplatin had good antitumor activity and was easy to combine with other agents because of mild myelotoxicity but was unpleasantly emetogenic and required hospitalization for complex pre-and post-treatment hydration to avoid nephrotoxicity. Early studies comparing platinum based and anthracyclin based regimens showed that while overall response rates can be higher in the anthracycline based regimens, there was little effect on survival. 23, 24 Subsequent studies consistently showed higher response rates with platinum containing regimens and longer survival as compared to non-platinum containing regimens (Table 4) . 4, 33 In a review of 21 published phase III trials for patients with extensive-stage (ED) SCLC identified through a search of the National Cancer Institute Cancer Therapy Evaluation Program database from 1972 to 1993, median survival times of patients treated on the control arms of the trials initiated from 1972 to 1981 was seven months and was 8.9 months for patients treated on trials from 1982 to 1990 (P=0.001). There has also been a significant trend toward prolonged survival time in patients treated on the control arms initiated over the entire period of the analysis (1972 to 1993, P=0.0001). The improvement in survival could be partly due to improvement in supportive care. However, the median survival time of patients treated with platinum based regimens (n=14) was 9.5 months compared to 7.1 months for patients treated with non-platinum based regimens (n=40) (P=0.04). Squares regression analysis showed that cisplatin based therapy and the year of study initiation were significantly related to median survival (P=0.04 and P=0.002, respectively). 25 A systemic review of 36 published randomized clinical trials (from 1980 to 1998) was conducted comparing regimens containing cisplatin (CDDP) and/or etoposide (VP-16) with others omitting the same drug(s) given as first-line therapy in SCLC patients. One trial tested a CDDP based regimen (without VP16) against another arm that did not include either CDDP or VP16. Survival hazard ratio with 95% confidence intervals was 0.70 (range 0.41-1.21). Nine of the trials in the review compared a regimen including CDDP and VP16 with a regimen using neither drug. Survival hazard ratio was 0.57 (range 0.51-0.64). Nine other trials included in the analysis compared a regimen based on both drugs with a regimen based on VP16 only. Survival hazard ratio was 0.74 (range 0.66-0.83). Overall survival benefits could also be shown for regimens including CDDP (HR=0.61, confidence interval (CI), 0.57-0.66). 31 A meta-analysis of 19 clinical trials (4,054 patients) randomizing a cisplatin-containing regimen versus a regimen without cisplatin was conducted. Patients randomized in a cisplatin-containing regimen had an increase in probability of being responders with an OR of 1.35, 95% confidence interval (CI) of 1.18-1.55, corresponding to an increase of objective (partial plus complete) response rate from 0.62 to 0.69. Patients treated with a cisplatin containing regimen benefited from a significant reduction in risk of death at six months and one year (OR 0.87, 95% CI 0.75-0.98, P=0.03 and OR 0.80, 95% CI 0.69-0.93, P=0.002, respectively). This corresponded to a significant increase in the probability of survival of 2.6% and 4.4% at six months and one year, respectively. 26 Another metaanalysis of 29 clinical trials (5530 patients) comparing results of platinum based chemotherapy versus non-platinum based chemotherapy showed no significant difference in overall tumor response or overall survival. However, a significant difference was seen in complete response rate in favor of platinum containing regimens. Results were not stratified according to extent of disease. 34 There is growing evidence showing an advantage for concurrent chemo-radiotherapy over sequential treatment (see below). To our knowledge, there have been no studies directly comparing platinum against non-platinum containing regimens in patients treated with concurrent chemo-radiotherapy. However, in a multi-institutional phase III study including 386 patients with LD-SCLC, the South-Eastern Cancer Study Group showed that the concurrent use of radiotherapy and CAV failed to improve the survival of LD-SCLC patients compared with CAV alone. The survival in patients treated with CAV (with or without RT) was improved with two cycles of cisplatin and etoposide consolidation therapy, resulting in superior median (21.1 vs 13.2 months, P=0.028) and 2-year survival (44% vs 26%, P=0.028) rates). 29 In another study, consolidation CAV after initial PE-based concurrent chemo-radiotherapy was not associated with increased survival but significant toxicity was observed. 30 PE combination therapy is also an effective second-line regimen. In platinum-naive patients the response rate is 40%. 35 The PE combination appears to be of benefit in patients who respond to primary treatment with CAV (RR=23%) whereas second-line therapy with CAV has less benefit after PE (RR=8%). 24 In 29 patients who received CAV after their tumors failed to respond or who relapsed after PE or carboplatin and etoposide, RR was 27.5% and the median survival was 15 weeks. 17 The response rates obtained by combination PE therapy or reinduction therapy were 45% and 64%, respectively. With P and E not given in combination the response rates were less than 20%. 19 Carboplatin, an analog of cisplatin, is a widely used platinum agent with less renal and neurological side effects as compared to cisplatin but more myelosuppression (especially thrombocytopenia). In studies in which patients were previously untreated, the overall response rate to single agent carboplatin was 59% and CR rate was 11%. In previously treated patients, overall response rate was 17% and CR rate was 4%. 36 Single agent carboplatin produces response rates, relief of tumor related symptoms, and survival similar to that seen in patients who receive CAV chemotherapy. This was shown in a randomized study comparing single agent carboplatin with CAV in patients with poor prognosis, poor performance status SCLC (n=119). Symptom relief occurred in 48% and 41% of patients in the CAV and carboplatin treatment arms, respectively. Dyspnoea was improved in 66% and 41% of patients and cough was improved in 21% and 7% of patients in the CAV and carboplatin treatment arms, respectively. CAV therapy produced a higher response rate than carboplatin (38% vs 25%), but this was not statistically significant (P=0.15). The median overall survival for patients in the CAV and carboplatin treatment arms was 17 weeks and 15.9 weeks, respectively. Grade 3-4 neutropenia and intravenous antibiotic use were significantly more common with the CAV regimen (P<0.005). Conversely, Grade 3-4 thrombocytopenia was more common (P<0.0009) and platelet transfusion was more frequent (P<0.05) with carboplatin therapy. Nonhematologic toxicity was similar in both treatment arms, except for alopecia with CAV therapy (P<0.0007). 32 The efficacy and toxicity of PE and carboplatin and etoposide (CaE) combinations along with thoracic irradiation have been prospectively assessed in only one study in 147 patients with SCLC. Both combinations were equally effective. The CR rates were 57% and 58% for PE and CaE, respectively. Median survival for all patients was 12.5 and 11.8 months, respectively. However, the CaE regimen caused significantly less nausea, vomiting, nephrotoxicity, and neurotoxicity, and it was easier to administer. Dose intensity and treatment delays were similar in both groups. 10 In the absence of other comparative data, cisplatin must be regarded as the standard option in limited stage disease, and consideration should be given to carboplatin based regimen in extensive stage disease due to favorable toxicity profile. Picoplatin is a novel platinum agent that showed modest activity in platinum refractory/resistant SCLC with a partial response rate of 4% and stable disease in 43%. Median overall survival was 26.9 weeks and toxicity was mainly hematologic. 37 
Addition of ifosfamide to platinum-containing regimens
Ifosfamide is an alkylating agent closely related structurally to cyclophosphamide by transposition of one of the side chain chloroethyl groups to the ring nitrogen. This minor structural change may account for the different pharmacological behavior of these two compounds as well as for their different spectrums of clinical activity and toxicity. Ifosfamide has activity in a variety of disseminated refractory solid tumors that do not traditionally respond to conventional alkylating agent therapy, specifically refractory germ cell tumors, soft tissue sarcomas, NSCLC and malignant lymphomas. This has encouraged investigators to test the activity of ifosfamide in SCLC. Available data indicate that single agent ifosfamide can produce 50% objective response rate in SCLC. 38, 39 Ifosfamide, platinum (cisplatin or carboplatin) and etoposide (ICE) yielded 71-87% over all response rates and a median survival of 36-42 weeks in patients with ED-SCLC. [40] [41] [42] [43] Ifosfamide has been included in platinum based regimens in phase II studies and has shown activity and lack of crossresistance. 44 Phase III studies investigating the role of adding ifosfamide to platinum based chemotherapy yielded conflicting results. In 92 SCLC patients randomized to receive PE or ICE (cisplatin) combination chemotherapy, there was no statistical difference in response rates, duration of response, median survival or 2-year survival. Severe leukopenia occurred more often after ICE (73%) than after PE (44%). 45 VIC (vincristine, ifosfamide and carboplatin) alternating with ACE did not improve survival or time to progression when compared to ACE in a phase III EORTC study. 46 On the other hand, the Hoosier Oncology Group randomized 171 patients with ED-SCLC to receive PE or IPE. There was a statistical difference in the median time to progression (P=0.039). The median survival times on PE and IPE were 7.3 months and 9.0 months, respectively (P=0.045) with 2-year survival rates of 5% versus 13%, respectively. Hematologic toxicity was more severe in the patients in the IPE arm, but both arms had a 6-7% treatment-related mortality rate. 47 The same group showed that ICE (oral etoposide) is an effective second-line treatment with 55% response rate in 46 patients with recurrent disease of whom 36 of 42 patients had received prior PE. 49 The MRC LU21 study compared vincristine, ifosfamide, carboplatin and etoposide (VICE) with standard treatment (78% ACE, 13% PE) in 402 patients. The median survival was 15.1 months for VICE and 11.6 months for standard treatment (P=0.026) with significantly more patients surviving at 12 and 24 months. 48 Overall, when added to platinum based regimens, ifosfamide may result in a modest improvement in outcome but at the expense of increased side effects, mainly myelotoxicity and nephro-urothelial toxicity (Table 5) .
Dose-intense chemotherapy
Theoretically, dose escalation can increase cell kill and overcome drug resistance. A variety of methods have been used to achieve increased cytotoxic dose intensity including the use of increased doses, shorter treatment intervals, hematopoietic growth factor support and hematopoietic progenitor cell support.
Suboptimal chemotherapy doses result in inferior survival, but it is not certain how far survival in SCLC patients can be improved by increasing dose intensity. An early study showed significantly higher response rates, median survival and long-term survival when the cyclophosphamide dose was increased from 0.5 to 1 g/m 2 body-surface area, lomustine from 50 to 100 mg/m 2 , and methotrexate increased from 10 to 15 mg/m 2 ( Table 6 ). 50 Many now consider the standard arm of this study to have been under-dosed.
A number of phase II studies investigated the effect of higher chemotherapy doses in the first 1-4 cycles (Table 7) , although no survival advantage was seen for this approach. Only one study showed a survival advantage for early dose intensification. In this study, 105 patients with LD-SCLC were randomly assigned to receive higher or lower initial doses of cisplatin (100 or 80 mg/ 2 ) and cyclophosphamide (300 or 225 mg/m 2 daily for four days) in the first cycle. All patients received the lower doses from the 2 nd through the 6th cycle of chemotherapy. The 2-year survival rate for the 55 patients who received the higher doses of chemotherapy was 43%, as compared with 26% for the 50 patients who received the lower doses (P=0.02). Disease-free survival at two years was 28% in the higher-dose group, as compared with 8% in the lower-dose group (P=0.02). There was no increase in side effects from treatment in the higher-dose group. 54 Phase III studies investigating dose intensity are summarized in Table 6 . Another approach to improve the dose intensity of chemotherapy is to reduce the interval between the cycles of chemotherapy with the use of hematopoietic growth factors with or without autologous peripheral blood progenitor cell rescue.
Review
The combination of cisplatin, vincristine, doxorubicin, and etoposide (CODE) was designed to double the dose intensity of these drugs in comparison with a standard regimen (alternating CAV/PE) for ED-SCLC. Dose intensity was increased by more frequent treatment administration rather than by increasing the size of the dose. CODE was investigated in 48 patients with ED-SCLC in a phase II study with encouraging results. 63 Ninety-four percent responded to chemotherapy, with 40% attaining CR. After consolidative thoracic irradiation, the CR rate was 56%. The median time to progression was 43 weeks, and the median survival was 61 weeks. The 2-year survival rate was 30%. Grade IV granulocytopenia occurred in 56% of patients. There were 2 treatment related deaths. However, a phase III study conducted in Japan failed to confirm any advantage with CODE over CAV/PE in patients with ED-SCLC. There was no difference in the incidence of leukopenia between the two arms, but there was a significantly higher incidence of anemia and thrombocytopenia in the CODE arm. Four treatmentrelated deaths from neutropenic fever occurred in the CODE arm. 55 In addition, a NCIC/SWOG phase III study was discontinued early because of excessive treatment related mortality in the CODE arm as compared to CAV/PE (8.2% vs 0.9%) with a non-statistically different median survival (0.98 vs 0.91 years). 56 Steward et al. randomized 300 patients with good or intermediate prognosis LD and ED-SCLC to six cycles of chemotherapy with ifosfamide 5 g/m 2 , carboplatin 300 mg/m 2 , etoposide 120 mg/m 2 intravenously on Days 1 and 2 and 240 mg/m 2 orally on Day 3, and vincristine 0.5 mg/m 2 i.v. on Day 15 (VICE) every three weeks (intensified arm) or every four weeks (standard arm). The planned RDI of the intensified arm was 1.33 and the overall actual delivered DI was 1.26. Survival was significantly increased in the intensified compared with the standard arm (P=0.0014). Myelosuppression was the main toxicity, with no significant difference in the incidence or grade between treatment groups. 57 This survival benefit was confirmed in another study in which 403 patients with LD and ED-SCLC were randomized to receive 6 cycles of ACE either every three weeks or every two weeks with G-CSF support. The received dose intensity was 34% higher in the accelerated arm. CR and survival were statistically better in the accelerated arm. In the accelerated arm, there was less neutropenia but more thrombocytopenia and more frequent blood and platelet transfusions. 58 Other trials failed to show survival benefit from accelerated chemotherapy. In a similarly designed study, 244 previously untreated SCLC patients were randomized to standard ACE (doxorubicin 45 mg/m 2 on Day 1, cyclophosphamide 1000 mg/m 2 and etoposide 100 mg/m 2 on Days 1-3 every three weeks, for 5 cycles) or intensified (higher dose and more frequent) ACE (doxorubicin 55 mg/m 2 on Day 1, cyclophosphamide 1250 mg/m 2 and etoposide 125 mg/m 2 on Days 1-3 with granulocyte colony-stimulating factor (G-CSF) 5 g/kg/d on Days 4 to 13 every two weeks, for 4 cycles). Delivered DI on the intensified arm was 70% higher than on the standard arm. Intensified ACE was associated with more grade 4 leukopenia (79% vs 50%), grade 4 thrombocytopenia (44% vs 11%), anorexia, nausea, and mucositis. Febrile neutropenia and number of toxic deaths were similar on the two arms. There was no statistical difference in response and survival rates. 59 This study failed to show survival benefit despite delivery of higher DI of 70% over the standard arm as compared to the study by Thatcher et al. that delivered 34% higher DI compared to the standard arm.
The European Lung Cancer Working Party (ELCWP) designed a 3-arm phase III randomized trial of 233 patients with ED-SCLC to: arm A, standard chemotherapy with 6 courses of EVI (epirubicin, vindesine, ifosfamide), all drugs given on Day 1 repeated every three weeks; arm B, accelerated chemotherapy with EVI administered every two weeks and GM-CSF support; arm C, accelerated chemotherapy with EVI and oral antibiotics (cotrimoxazole). There was, however, no difference in 2-year survival (5% for arm A, 6% for arm B and 6% for arm C). 60 Sixty published studies in LD and ED SCLC were retrospectively analyzed for any relationship between intended dose intensity (DI) and response or median survival. For CAV, increasing RDI of the regimen showed no correlation with outcome. For the individual drugs, C RDI correlated positively, while A RDI correlated negatively with achievement of CR in limited disease, but both only after unduly influential observations were eliminated. In extensive-stage disease, A RDI correlated positively with CR and PR but only in randomized trials, and this correlation lost statistical significance after unduly influential observations were eliminated. For CAE and CAVE, the RDI of the regimens correlated positively with median survival in extensive-stage disease as did the C RDI. In limited disease, the C RDI correlated negatively with median survival. For EP, no significant correlations were seen. The authors concluded that DI-outcome correlations are not consistent for these chemotherapy regimens in SCCL. 64 Hematologic growth factors with the support of autologous peripheral blood progenitor cell rescue may allow further acceleration of chemotherapy delivery. In a feasibility study, Woll et al. confirmed this hypothesis when they randomized 50 consecutive SCLC patients with a favorable prognosis to receive 6 cycles of ifosfamide, carboplatin, and etoposide (ICE), at 4-week (standard treatment) or 2-week (intensified treatment) intervals. Intensified treatment was supported by daily subcutaneous filgrastim injections and reinfusion of autologous blood collected immediately before each cycle. Over all 6 cycles, the median received DI was 0.95 for the standard treatment arm and 1.60 for the intensified treatment arm (P<0.001). Febrile neutropenia was more common on the standard treatment arm (84% vs 56%) resulting in more days of intravenous antibiotics (median 10 vs 3 days, P=0.035). Transfusion requirements were similar in the two groups. 61 This study was extended to a phase III trial using the support of hematologic growth factors and autologous peripheral blood progenitor cells rescue, Lorigan et al. confirmed the ability to deliver 1.82 of ICE dose intensity in 2-weekly intervals as compared to 0.99 DI in the standard arm (4-weekly) in 318 patients with adverse prognostic SCLC and PS 1-2. However, median survival was similar in both groups. 62 To date, there has been only one randomized phase III trial (Table 8 ) completed in patients with SCLC investigating the role of high-dose chemotherapy and hematologic stem cell transplantation. 6 In this study, 101 patients with LD or ED-SCLC receive induction chemotherapy consisting of methotrexate, vincristine, cyclophosphamide and doxorubicin followed by prophylactic cranial irradiation followed by 2 cycles of cisplatin and etoposide. Forty-five patients, selected for their sensitivity to this induction treatment, were randomized to a last cycle of chemotherapy that combined cyclophosphamide, BCNU, and VP-16-213 either at a conventional dosage of 750 mg/m 2 i.v., 60 mg/m 2 i.v., and 600 mg/m 2 orally or alternatively at a very high dosage of 6 g/m 2 i.v., 300 mg/m 2 i.v., and 500 mg/m 2 i.v., respectively. In the late intensification group, the CR rate increased from 39% before randomization to 79% after high-dose chemotherapy. Median relapse-free survivals after randomization for intensified and control chemotherapy groups were 28 and 10 weeks, respectively (P=0.002). However, median survival after induction therapy was 68 weeks for the intensified group compared with 55 weeks for the conventional therapy group (P=0.13). Four patients died from treatment related complications in the high-dose chemotherapy arm.
Two retrospective reviews are worth mentioning in this context. The first included 36 patients with only LD-SCLC selected on the basis of their continued response to first-line therapy, their relative lack of significant co-morbidity, and their ability to obtain financial clearance. The 2-and 5-year survival rates after dose intensification were 53% and 41%, respectively. Of 29 patients who were in or near CR before undergoing high-dose therapy, 14 (48%) remain continuously progression free at a median of 61 months (40-139 months) after high-dose therapy. Overall 2-and 5-year PFS rates were 57% and 53%, respectively. The procedure-related mortality was 8%. 7 The second review by Rizzo et 8 In a feasibility study, 8 of 11 patients (4 LD and 4 ED) with adequate organ function were treated with HD-ICE (15 g/m 2 ifosfamide, 1200 mg/m 2 carboplatin and 1500 mg/m 2 etoposide) followed by ABPCT. Hematologic recovery was rapid and non-hematologic toxicities were acceptable without treatment-related mortality. In ED-SCLC, all of the 4 patients achieved CR or near CR but developed a relapse of the disease. In LD-SCLC, 2 of 4 patients are alive in continuous CR for 18 and 21 months after the beginning of induction therapy. 9 Overall, there is some evidence for improved survival with dose intensity through treatment acceleration and hematologic growth factor support. However, further dose intensification requiring autologous peripheral blood progenitor cells or stem cell rescue has not yet been proved to improve survival and further randomized studies are required.
[Oncology Reviews 2012; 6:e4]
[page 23] 

Newer agents
Although improvements have been made in the treatment of SCLC, the overall results remain disappointing with only a small percentage of patients achieving long-term survival. Active newer agents are clearly needed. Several new agents have been studied and have demonstrated significant activity.
Irinotecan (CPT-11)
Irinotecan (CPT-11) is a topoisomerase I inhibitor (Table 8) . Single agent irinotecan in 2 phase II studies shows overall response rates of approximately 16% and 47% in previously treated patients. 65, 66 Adding cisplatin to irinotecan yields higher RRs. [67] [68] [69] Based on these results, a multicenter phase III trial was conducted comparing irinotecan/cisplatin (IP) and PE in ED-SCLC. At the interim analysis, 154 patients had been enrolled. Enrolment was closed early because interim analysis showed significantly superior survival in patients assigned to receive IP. 70 However, results of other randomized trials conducted outside Japan failed to confirm these findings. A multicenter, open-label, randomized trial in chemo-naïve patients with ED-SCLC using a modified weekly regimen of IP versus PE to improve tolerability and achieve greater dose intensity showed no significant differences in RRs and OS in this patient population. Patients receiving IP had less myelosuppression but more diarrhea than those receiving PE. 71 The Southwest Oncology Group (SWOG S0124) trial showed no difference in response rates, progression free survival or overall survival in 651 patients randomized to received PE or IP in arms identical to those in the Japanese JCOG 9511 trial. 78 When studied in combination in a first-line setting, irinotecan and etoposide yielded response rates of 60-66% and median survival of 9.9-11.5 months. 71, 78 Other phase II studies investigated irinotecan in combination with other agents (gemcitabine, ifosfamide, carboplatin or etoposide) in previously treated patients with RRs of 10-71% (Table 9) . Irinotecan was added to the standard combination (cisplatin and etoposide). This 3-drug combination was evaluated in 40 patients who responded to first-line chemotherapy but relapsed more than eight weeks after the completion of first-line therapy. The overall response rate was 78% (95% CI 61.5-89.2%). The median survival time was 11.8 months, and the estimated one-year survival rate was 49%. Grade 3-4 leukocytopenia, neutropenia, and thrombocytopenia were observed in 55%, 73%, and 33% of the patients, respectively. 77 
Topotecan
Topotecan is another topoisomerase I inhibitor ( Table 9 ). Single agent topotecan yields an overall response rate of 39%, median survival of 10.0 months and a one-year survival rate of 39% in previously untreated ED-SCLC. 79 Studies evaluating single agent topotecan in refractory and relapsed patients report 3-11% and 15-37.8% response rates, respectively. [80] [81] [82] [83] 90 In the EORTC 08957 phase II study, combined topotecan and cisplatin (TP) yielded overall response rates of 29.4% and 23.8% and median survival of 6.4% and 6.1% months in chemo-sensitive and chemorefractory previously treated patients, respectively. 80 Christodoulou et al. reported 7.8 and 6.2 months median survival with this combination in relapsed and refractory patients. 84 Topotecan in combination with either cisplatin or etoposide in patients with untreated ED-SCLC showed similar RRs (63% and 61%) and median survival (10.1 and 9.6 months), respectively. 85 In a large phase III study, topotecan/cisplatin (TP) and PE showed comparable activity in previously untreated patients with ED-SCLC. There were less incidences of grade 4 neutropenia (26% vs 56.8%) and associated fever (3.9% vs 8.9%) with TP as compared to PE. 86 The combinations (topotecan and cyclophosphamide) in relapsed patients and (topotecan and paclitaxel) in chemo-naïve ED patients yields RRs and median survival of 40.5% and 9 months and 69% and 12.7 months, respectively. 87, 88 Topotecan and CAV were evaluated in a randomized, multicenter study of 211 patients with SCLC who had relapsed at least 60 days after completion of first-line therapy. There was no statistical difference in RRS, PFS and median survival. Greater symptomatic improvement was seen in patients who received topotecan for symptoms of dyspnea (P=0.002), anorexia (P=0.042), hoarseness (P=0.043), and fatigue (P=0.032), and for interference with daily activities (P=0.023). Grade 4 neutropenia occurred in 37.8% of topotecan courses versus 51.4% of CAV courses (P<0.001). There were more frequent incidences of grade 4 thrombocytopenia and grade 3-4 anemia with topotecan. 89 Based on these findings, topotecan was approved by the Food and Drug Administration for treatment of recurrent disease.
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Overall, topotecan demonstrates antitumor activity in both chemosensitive and refractory disease. Furthermore, topotecan therapy is associated with significant symptom palliation in this patient population. Since topotecan has a predictable toxicity profile (toxicity is generally manageable and non-cumulative), the agent is also potentially useful in patients with a poor prognosis and/or a poor performance status. Alternative dosing regimens (lower dose, weekly) and the introduction of an oral formulation may expand the use of topotecan both as a single agent and in combination therapy in the second-and first-line treatment of this disease.
Paclitaxel
Paclitaxel is an antimicrotubule agent that interferes with cell division (Table 10 ). It has well documented broad spectrum cytotoxic activity and is now licensed for use in many solid tumors including breast, ovary and non-small cell lung cancer. Overall response rate was 34% and 53% when single agent paclitaxel was investigated in previously untreated patients with ED-SCLC and 29% in patients with refractory disease. [91] [92] [93] Doublets of paclitaxel and carboplatin or etoposide yield RRs of 38% and 63.6% in first-line treatment of patients with ED-SCLC. 94, 95 The triplet PET (cisplatin, etoposide and paclitaxel) achieved a RR of 90% including CR of 16% and median survival of 11 months in chemonaïve ED patients. 96 Lower RRs (57%) were seen with a similar regimen treating similar group of patients. 98 boplatin, the RR was 84% and 98% in ED and LD patients, respectively. 97 PET was not statistically superior to PE and imposed more hematologic and non-hematologic toxicity. 99, 100 However, a randomized phase III multicenter showed better outcome with carboplatin, etoposide and paclitaxel (CET) when compared to carboplatin, etoposide, and vincristine (CEV) in patients with previously untreated LD and ED-SCLC. The hazard ratio of death and PFS were statistically significantly better in patients on CET. There were no differences in CEV: (69.4%) and CET (72.1%). Rates of severe grade of anemia, leukocytopenia, neutropenia, and thrombocytopenia were lower in the CET arm than in the CEV arm. Rates of leukocytopenia, neutropenia, and febrile neutropenia were similar among patients in both arms. 101 It is possible that the use of carboplatin in this study improved the toxicity profile in CET when compared to studies using cisplatin (PET). The triplet carboplatin, paclitaxel and topotecan provided no apparent improvement in efficacy. 102 
Docetaxel
Docetaxel is another antimicrotubule agent with broad spectrum cytotoxic activity [103] [104] [105] [106] [107] [108] (Table 11 ). Phase II studies showed only limited activity in SCLC. In previously treated patients, the response rate was 25%. 103 In previously untreated patients, the response rates (all PR) in 2 studies were 8.3% and 23%. 104, 105 In previously treated patients, the combination of docetaxel and gemcitabine showed disappointing results with no response seen in 22 patients. 106 In previously untreated patients, docetaxel in combination with gemcitabine was assessed in ED-SCLC. Only 6 patients showed a partial response and the trial ended prematurely since at least seven responses were required among the first 19 patients. 107 In similar patients, the combination showed some activity (RR 23%). 108 Over all, early studies with docetaxel did not show promising results. This may explain why available data are scarce. It should not be considered in treatment of SCLC outside clinical trials.
Vinorelbine
Vinorelbine is a semisynthetic vinca alkaloid (Table 12 ). In small phase II studies, single agent vinorelbine yielded only modest response rates of 0-16% in previously treated and untreated patients. [109] [110] [111] [112] [113] Higher responses (55%) were shown in 2 studies combining vinorelbine and carboplatin. However, this combination was found to be extremly toxic, including toxic deaths. The authors concluded that this combination is active but the toxicity profile is such that further evaluation is not considered appropriate. 114, 115 Combining vinorelbine with doxorubicin was also found to be very toxic. Johnson et al. reported a 26.7% response rate. Toxicities included grade 4 neutropenia in 73% and febrile neutropenia and/or sepsis in 60%. Three patients died from sepsis during the first cycle of treatment. 116 A combination of the 2 new agents, vinorelbine and gemcitabine, has shown only modest activity with RRs of 6-10% in previously treated patients. [117] [118] [119] From the evidence available, single agent vinorelbine provided only modest results but using it in combination with other cytotoxic agents yields moderate activity; however, the toxicity profile is unacceptable.
Gemcitabine
Gemcitabine is a pyrimidine nucleoside antimetabolite that, through incorporation into the DNA, leads to inhibition of DNA synthesis and cytotoxicity (Table 13) . Response rates to single agent are at best 13% in refractory and relapsed patients and 27% in previously untreated patients. [120] [121] [122] [123] In 42 previously untreated ED-SCLC, combination gemcitabine and etoposide yielded an overall response rate of 46% and median survival of 10.5 months. 124 Doublets of gemcitabine and other agents, for example, irinotecan, vinorelbine and cocetaxel yield poor response rates of no more than 17% in pre-treated patients. [125] [126] [127] [128] [129] [130] In the first-line setting in poor performance elderly patients with ED, gemcitabine and docetaxel resulted in an unimpressive RR of 23% and median survival of four months. 131 The was 8.1 and 8.2 months for GC and PE, respectively. 132 Complete results of this study are still awaited. In a phase I/II study, the triplet combination of cisplatin, etoposide, and gemcitabine (PEG) was investigated. In the phase I section of the study, etoposide dose of 50 mg/m 2 was defined as the maximum tolerated dose (MTD). In the subsequent phase II evaluation, 48 additional patients were enrolled. PEG showed an overall response rate of 72.2% and one-year survival of 37.5% in 56 previously untreated patients with LD or ED SCLC. 133 This study was followed by a randomized phase II study by the same group comparing PEG and PG. The objective response rate was 63% for PEG and 57% for PG, with the suggestion of a higher complete response rate in the PEG arm (18.6% and 4.3%, respectively). A similar time to disease progression (6 months in the PEG arm and 7 months in the PG arm) and a similar median survival (9.5 months in the PEG arm and 10 months in the PG arm) were observed in both arms. The PEG regimen was associated with more severe hematologic toxicity in terms of neutropenia, febrile neutropenia, and a higher rate of treatment delays and dose reductions, whereas there was no difference in non-hematologic toxicities between the two arms. 134 From the available evidence, gemcitabine has shown promising results when combined with platinum derivatives as a doublet or with platinum derivatives and etoposide as a triplet. However, this evidence is reported in ED and poor prognosis patients. It would be interesting to investigate these regimens in a group of patients with better prognosis.
Review
Amrubicin
Amrubicin is a synthetic anthracycline that has shown significant activity in SCLC and has minimal cardiac toxicity. It is approved in Japan for treatment of SLCL. Phase II studies showed significant response rates when used as single agent or in combination with platinum agents (Table 14) in the upfront setting. In the relapsed setting, phase II studies also showed promising results, with a hint of superiority over topotecan. [140] [141] [142] [143] The dose of amrubicin is 35mg/m 2 daily for three days. A recently presented phase III trial randomized 637 platinum pre-treated patients to receive either topotecan or amrubicin. Preliminary results of this study showed non-inferiority of amrubicin, but there was no significant improvement in primary end point of overall survival. However, progression free survival (4.1 vs 3.5 months, P=0.02) and response rates (31% vs 17%, P=0.0001) improved significantly with amrubicin. The overall incidence of febrile neutropenia was higher in the amrubicin group (9.3% vs 6.3%) but there was no incidence of cardiotoxicity. 146 
Combined modality treatment
Despite the improvement in survival with the widespread use of chemotherapy for SCLC, 30-80% of patients will develop local recurrence. The use of radiotherapy in addition to chemotherapy has, therefore, been investigated. The role of radiotherapy in the management of SCLC is outside the scope of this review. However, this section briefly presents some of the landmark findings in this treatment method when used in conjunction with chemotherapy.
Review
A meta-analysis of 13 randomized trials clearly demonstrated a significant survival advantage of 5.4% at three years for combined modality in LD-SCLC. 147 Pooling data from 8 randomized controlled trials enrolling over 1,500 patients showed that early integration of chest radiotherapy with systemic chemotherapy increases OS by 34-216%, depending on the end point of interest. Etoposide plus cisplatin in conjunction with chest irradiation appears to offer the greatest increase in survival versus delayed or split-course radiation therapy and non-PE containing drug schedules. 148 The optimal dose and fractionation schedule of radiotherapy is still uncertain. Turrisi et al. demonstrated a longer survival in favor of twice daily as compared to once daily concurrent chemo-radiotherapy. 149 This is confirmed by the meta-analysis of 7 RCTs which showed 2-year overall survival relative risks compared with late radiotherapy as follows: RR 1.17, 95% CI 1.02-1.35 in favor of early radiotherapy; RR 1.44, 95% CI 1.17-1.83 in favor of hyperfractionation; RR 1.30, 95% CI 1.10-1.53 in favor of early radiotherapy added to platinum based chemotherapy. 150 Use of concurrent radiotherapy with chemotherapy as opposed to sequential was compared in a Japanese Clinical Oncology Group study. 151 There was a marked improvement in median and overall survival in favor of the concurrent chemo-radiotherapy group, but this did not reach statistical significance. In the UK, sequential treatment is the current standard management of patients with LD-SCLC. However, some centers are starting to recommend concomitant treatment. Further research is required to investigate the role and the best scheduling of sequential chemotherapy.
Prophylactic cranial irradiation (PCI) is used in patients with LD-SCLC who had CR to initial treatment. This intervention reduces the risk of brain metastases by about 45% and may improve OS. Larger doses of radiation have led to greater decreases in the risk of brain metastasis. 152, 153 An ongoing international phase III study is investigating the effect of radiotherapy dose. The study randomizes patients with LD-SCLC in CR to 25 Gy in 10 fractions versus 36 Gy in 18 fractions or hyperfractionation regimen.
A phase III EORTC trial investigated the role of PCI in ED-SCLC in CR or PR. PCI resulted in a significant decrease in incidence of new brain metastases and appeared to increase overall survival. One-year survival was significantly increased from 13% to 27%. 154 PCI is offered routinely to LD-SCLC patients in CR or very good PR. Further trials are needed in patients with ED-SCLC to determine optimal dose of radiation and to determine which patients would derive most benefit.
Novel biological approaches
Innovative applications of conventional chemotherapy agents have not improved long-term outcome to any great extent despite a modest increase in response rates. Clearly innovative approaches are needed to significantly improve the prognosis. It has been recognized that tumor vascularization is a vital process for the progression of solid tumors from a small, localized focus to a large tumor with the capability of metastasizing. Such observations have resulted in a large number of drugs being developed intentionally, or positioned as angiogenesis inhibitors and these have been evaluated in pre-clinical and clinical trials. 155 High pre-treatment serum VEGF is associated with poor response to treatment and unfavorable survival in patients with SCLC treated with combination chemotherapy. 156 Thalidomide is an inhibitor of angiogenesis induced by basic fibroblast growth factor in a rabbit cornea micropocket assay and inhibits vascular endothelial growth factor (VEGF)-induced corneal neovascularization. [157] [158] [159] Anti-tumor activity of thalidomide has been demonstrated against glioma, renal cell carcinoma, multiple myeloma and prostate cancer. A phase II study of maintenance thalidomide undertaken in patients who responded to conventional chemotherapy showed median survival from time of initiation of induction chemotherapy of 12.8 months and oneyear survival of 51.7%. Thalidomide was well tolerated with median duration of treatment of 79 days. 160 In a phase II study, the London Lung Cancer group investigated thalidomide in patients with SCLC in combination with chemotherapy and as a maintenance therapy in an attempt to improve the outcome. Preliminary data appeared to show promising clinical activity. Thalidomide was well tolerated without adding to the expected toxicity of chemotherapy or radiotherapy. 161 Based on these findings the investigators extended the study into a randomized double blind phase III trial to test whether the addition of thalidomide to chemotherapy improves survival, time to tumor progression, performance status and quality of life as compared to chemotherapy alone (carboplatin and etoposide). The study recruited a total of 724 patients (51% with limited and 49% with extensive stage disease) with randomization to placebo or oral thalidomide 100 to 200 mg daily. There was no difference in survival mong patients with limited stage disease, but survival was worse in the thalidomide arm in patients with extensive stage disease. Thalidomide was also associated with increased risk of thromboembolism (19% with thalidomide vs 10% with placebo, P<0.001), as well as more rash, constipation and neuropathy. There was no difference in median overall survival between the two arms (10.5 months in placebo and 10.1 months in the thalidomide arm, P=0.28). 162 Bevacizumab, which is a novel anti-angiogenic agent with activity against circulating VEGF has also been studied in SCLC. A phase II study combining paclitaxel and bevacizumab in relapsed chemosensitive SCLC showed median progression free survival of 14.7 weeks (equivalent to historic controls), an overall response rate of 18.1% and median survival time of 30 weeks. No unexpected toxicities were noted. 163 In the first-line setting, 3 phase II trials have evaluated the addition of bevacizumab to platinum based chemotherapy. Response rates ranged from 63.5% to 84%, and median survival of 10.9 to 12.1 months was achieved. No significant toxicities from addition of bevacizumab were noted. [164] [165] [166] A phase III trial randomizing untreated ES-SCLC to chemotherapy alone versus addition of bevacizumab is underway (ClinicalTrials.gov identifier NCT00930891). Sorafenib is an oral small molecule tyrosine kinase inhibitor affecting multiple pathways involved in progression and angiogenesis. A phase II study of single agent sorafenib in platinum treated patients, however, failed to show adequate disease control, 167 and combination trials of sorafenib and chemotherapy are underway.
CD56 is a neural cell adhesion molecule (NCAM) expressed on the cells of tumors of neuroendocrine origin including SCLC, carcinoid tumors, neuroblastomas and on neuroectodermal tumors such as astrocytomas. It is expressed in almost all cases of SCLC. 168 BB-10901 is an immunoconjugate created by the conjunction of the cytotoxic maytansinoid drug DM1 to a humanized version of the murine antibody N901. BB10901 binds with high affinity to CD56, the conjugate is internalized and releases DM1. Released DM1 inhibits tubulin polymerization and microtubule assembly causing cell death. Four centers in the UK are conducting a phase II study which started in April 2003 to evaluate the safety, tolerability, pharmacokinetics and efficacy of BB-10901 in patients with relapsed or refractory SCLC or other CD56 expressing tumors.
Various novel targeted agents have been investigated in SCLC. About 80% of SCLC cells express c-Kit. However, imatinib, a c-Kit inhibitor, has shown has shown disappointing results in SCLC. [169] [170] These studies recruited 19 and 29 patients, respectively. There were no responders. Increased expression of metalloproteinases (MMP) is associated with poor prognosis. In a phase III NCI/EORTC study, 532 SCLC patients in complete or partial remission were randomized to receive marimastat (MMP inhibitor) 10 mg or placebo orally for up to two years. The median time to progression for marimastat patients was 4.3 months compared with 4.4 months for placebo patients (P=0.81). Median survival for marimastat and placebo patients were 9.3 months and 9.7 months, respectively, (P=0.90). Toxicity was generally limited to musculoskeletal symptoms (18% grade 3/4 for marimastat). Patients on marimastat had significantly poorer quality of life at three and six months. 171 R115777 is an oral, non-peptidomimetic farnesyl transferase inhibitor which blocks the activity of farnesylated proteins (e.g. ras or rhoB) involved in signal transduction pathways critical for cell proliferation and survival. There were no responders in 22 patients. 172 The phosphatidylinositol 3' kinase/AKT pathway may play an important role in the proliferation of SCLC. The mammaliam target of rapamycin (mTOR) is a downstream target in this pathway. In a phase II study, 87 patients with ED-SCLC in CR, PR or SD were randomized to 2 dose levels of temsirolimus (an inhibitor of mTOR). The median survival for all patients is 19.8 months. 173 These are considered to be favorable survival figures. However, they need to be confirmed in a phase III setting. A newer mTOR inhibitor everolimus (RAD001) was evaluated as a single agent in a phase II study in 40 previously treated SCLC patients. Everolimus was well tolerated but had limited single agent anti-tumor activity. 174 Further evaluation of everolimus in combination with chemotherapy is a subject of ongoing trials.
The proteasome inhibitor PS-341 inhibits growth of SCLC cell lines through decreased bcl-2 via NFk-B. In a phase II study, previously platinum-treated patients with ED-SCLC were treated with PS-341; 57 were evaluable for response. Seven patients discontinued treatment due to adverse events or side effects from therapy. There was only one responder to PS-341. 175 One novel approach to the treatment of lethal residual disease relies on the induction of a host-immune response to attack chemoresistant tumor cells. Because of its neuroectodermal origin, SCLC has a number of specific antigens that could be used as immune targets.
Interferon may have immune-modulating properties. It failed to show any positive impact on the survival outcome of patients with LD-SCLC. If anything, it may increase the deleterious effects of radiation on normal lung tissue. 176 Immunotherapy with immunological adjuvants such as MER-BCG did not prolong the time to disease progression or improve survival. 177 Immunization of patients with SCLC after standard therapy using antiidiotypic antibody such as BEC2, which mimics the ganglioside GD3 expressed on the surface of most SCLC tumors is another approach. 178 However, a randomized phase III EORTC study showed that vaccination with BEC2/BCG has no impact on the outcome of patients with LD-SCLC. 179 Further studies using vaccines that produce a better immunological response may be warranted.
The anti-apoptotic Bcl-2 proteins have been associated with a more aggressive malignant phenotype and chemoresistance in various cancer types including small cell lung cancer. 180 Oblimersen, an anti-sense oligonucleotide agent with activity against Bcl-2, was evaluated in a phase II clinical trial in SCLC but failed to show additional activity in combination with chemotherapy. 181 More recently, a Bcl-2 antagonist, obatoclax mesylate, was evaluated in combination with topotecan in relapsed SCLC. The combination also failed to improve on historic response rates seen with topotecan alone in relapsed SCLC. 182 Overall, it seems that it is going to be a long time before we can achieve impressive results with these novel approaches.
Conclusions
Combination chemotherapy is the current strategy of choice for treatment of SCLC. Platinum containing combination regimens are superior to non-platinum regimens in LS-SCLC and possibly also in ED-SCLC as first and second-line treatments. The addition of ifosfamide to platinum containing regimens may improve the outcome but this may be achieved with increased toxicity. Suboptimal chemotherapy doses result in inferior survival. Early intensified, accelerated and high-dose chemotherapy gave conflicting results and are not considered to be standard options outside clinical trials. A number of newer agents have shown promising results when used in combination regimens, e.g. gemcitabine, irinotecan and topotecan. However, more studies are needed to evaluate these agents. The role for radiotherapy in LD-SCLC has now been definitively confirmed. However, timing and schedule are subject to further research. Novel approaches are currently being investigated in the hope of improving outcome.
